GLP-1 Treatment Costs in Australia: What to Budget For, Including Bloods

Read this first

FORM is a pathology testing service. We do not prescribe, dispense, sell, compound or arrange supply of any GLP-1 medicine, we do not quote prices for medicines, and nothing here should be read as an offer, a recommendation or a statement that any medicine is available.

GLP-1 receptor agonists are Schedule 4 Prescription Only Medicines in Australia, and advertising prescription medicines to the public is prohibited under the Therapeutic Goods Act. That is a legal constraint on what any Australian website may publish, and it is also the reason this page deliberately does not contain a price list, a brand comparison or any commentary on which medicine anyone should be taking.

What this page does contain is the structure of the costs involved in medically supervised metabolic treatment — the categories, who sets them, and which ones people routinely forget to budget for. That is general consumer information, and it is genuinely useful, because the number most people arrive with is only one of five.

Where actual dollar figures matter, the only reliable sources are your pharmacist (for a dispensed price), the PBS website (for co-payment amounts and current listings), and your GP's practice (for consult fees). We link to the government sources rather than restating figures that change.

The five cost categories in medically supervised treatment

Total cost is not the medicine alone: it is the initial consultation, pathology, the prescription itself, follow-up consultations, and repeat pathology over time.

Breaking the cost into categories is more useful than a single number, because the categories behave differently. Two of them are set by government schedules, two are set by individual practices, and one varies pharmacy by pharmacy on the same street.

The table below sets out who controls each category and where the real variation sits. No dollar figures are given for the medicine itself, for the reason explained above — your pharmacist can quote that, and no one else reliably can.

PBS versus private scripts: why the same medicine costs different amounts

A medicine subsidised under the Pharmaceutical Benefits Scheme costs the patient a capped co-payment set by government; the same medicine on a private script is charged at whatever the pharmacy sets, with no cap.

This is the single biggest driver of cost difference in Australia, and it is the point most cost articles skip. PBS listings are indication-specific: a medicine can be subsidised when prescribed for one condition and not subsidised at all when prescribed for another, even though it is the same product. Whether a given person pays a co-payment or a private price is therefore determined by clinical criteria, not by shopping around.

Concession card holders pay a lower co-payment than general patients, and the PBS Safety Net reduces costs further once a household's annual spend passes a threshold. Both amounts are indexed annually and published on the PBS website, which is the only source worth trusting for a current figure.

For private scripts there is no equivalent cap. Pharmacies set their own prices, and the variation between a discount chain and an independent pharmacy on the same medicine can be meaningful. Asking two or three pharmacies for a dispensed price is legitimate and normal.

• PBS status is decided per indication, not per medicine — check the current listing at pbs.gov.au rather than assuming.
• Concession and Safety Net thresholds change each January; the published amount is the reliable one.
• For a private script, only a pharmacist can quote you a dispensed price, and prices differ between pharmacies.
• Compounded preparations are a separate regulatory category with their own risks; the TGA has published safety warnings about compounded GLP-1 products, and we take no position beyond pointing to that.

The line item most people forget: pathology

Bloods are a recurring cost across the whole course of treatment, not a one-off, and how they are requested determines whether you pay for them.

If your treating GP requests pathology and the test meets Medicare Benefits Schedule criteria for your clinical situation, it is generally bulk-billed and costs you nothing. That is the cheapest route and, where it is available to you, the sensible one. It requires a GP who is engaged with your care and willing to request the markers.

Privately requested pathology — where you order the test yourself without a treating-doctor referral — is paid in full and attracts no Medicare rebate and no private health insurance benefit. What it buys is speed, choice of markers, and a report you own without needing an appointment first. It is worth what it is worth to you; it is not cheaper than bulk-billed GP pathology.

Either way, budget for pathology more than once. A baseline plus a three-month repeat plus six- to twelve-monthly monitoring is the conventional pattern, and it means the pathology line recurs for as long as treatment does.

Whatever it costs, these are the bloods worth having

The baseline set is HbA1c, fasting glucose, a full lipid panel, liver function tests and thyroid function — the markers that make any later result interpretable.

This is the part of the cost question we can actually help with. Regardless of what any medicine costs, what route you take, or whether treatment happens at all, having these five documented before anything changes is cheap relative to everything else in the list and disproportionately useful later.

HbA1c and fasting glucose describe where glucose metabolism sits and, once repeated, which way it is heading. The lipid panel — particularly triglycerides — moves relatively quickly with weight and dietary change, so it is an early indicator of direction. Liver function tests matter because fatty liver is common, silent and travels with insulin resistance; a baseline ALT is what makes a later mildly raised ALT interpretable rather than alarming. Thyroid function is the standard check before unexplained weight change in either direction is attributed to anything else.

The full breakdown of each marker, with Australian reference ranges and sensible retest timing, is on our GLP-1 monitoring panel page.

• No referral from your own GP is required. Privately requested pathology is arranged under a request from a registered medical practitioner working with our accredited lab partner.
• Collection is a walk-in blood draw at Laverty (Healius) pathology centres Australia-wide (NATA / ISO 15189 accredited).
• Results are returned in Australian SI units — mmol/mol and % for HbA1c, mmol/L for glucose and lipids, U/L for liver enzymes — with a written plain-English explanation.
• Your results are yours. Take them to your GP, an endocrinologist or whichever registered practitioner is managing your care; decisions about any medicine are theirs and yours, not ours.
• Australian ordering is currently pre-sale. Join the waitlist and we will email you when ordering opens.

Where to test these markers

The baseline metabolic set is carried by the standard FORM Australia panels and can also be assembled marker by marker in the custom builder.

• GLP-1 monitoring blood panel — The full marker-by-marker breakdown, Australian ranges and a conventional retest schedule.
• Australian blood test panels (Essential to Ultra) — Essential covers the whole baseline metabolic set; indicatively from A$299 in pre-sale.
• Build your own Australian panel — Cheaper if you only want HbA1c, glucose, lipids, LFTs and TSH and nothing else.
• HbA1c test — Diagnostic thresholds, mmol/mol to % conversion, and the conditions that distort the result.